Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016
暂无分享,去创建一个
[1] Lin Wang,et al. Mixed histiocytosis: A case report and published work review , 2018, The Journal of dermatology.
[2] C. Fletcher,et al. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling , 2018, Modern Pathology.
[3] F. Munier,et al. Juvenile xanthogranuloma involving concurrent iris and skin: Clinical, pathological and molecular pathological evaluations , 2017, American journal of ophthalmology case reports.
[4] A. Tzankov,et al. PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma , 2018, Annals of Hematology.
[5] P. Thorner,et al. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. , 2017, Human pathology.
[6] Joseph D Khoury,et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease , 2017, Modern Pathology.
[7] A. Rosenwald,et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases , 2017, Virchows Archiv.
[8] A. Tzankov,et al. Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease , 2017, Virchows Archiv.
[9] P. Parkin,et al. The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case‐control study , 2017, Journal of the American Academy of Dermatology.
[10] R. Cason,et al. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations , 2017, Modern Pathology.
[11] D. Wheeler,et al. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma , 2017, Oncotarget.
[12] A. Wicki,et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. , 2017, Blood.
[13] J. D. van der Walt,et al. Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow , 2017, Annals of Hematology.
[14] B. Rollins,et al. Histiocytoses: emerging neoplasia behind inflammation. , 2017, The Lancet. Oncology.
[15] H. Deeg,et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] O. Abdel-Wahab,et al. Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses , 2016 .
[17] T. Qiu,et al. High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms , 2016, Oncotarget.
[18] A. Cherry,et al. Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. , 2016, Human pathology.
[19] O. Abdel-Wahab,et al. Histiocytic neoplasms in the era of personalized genomic medicine , 2016, Current opinion in hematology.
[20] R. Shackelford,et al. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment , 2016, European journal of haematology.
[21] B. Woda,et al. Somatic mutations in histiocytic sarcoma identified by next generation sequencing , 2016, Virchows Archiv.
[22] A. Fischer,et al. Revised Classification of Histiocytoses and Neoplasms of the Macrophage-dendritic Cell Lineages Histiocyte and Dendritic Cell Lineages the " L " (langerhans) Group , 2022 .
[23] S. Fröhling,et al. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling , 2016, Leukemia.
[24] A. Hoischen,et al. Independent development of lymphoid and histiocytic malignancies from a shared early precursor , 2016, Leukemia.
[25] M. Kluk,et al. Rosai–Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation , 2016, Head and Neck Pathology.
[26] B. Taylor,et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. , 2016, Cancer discovery.
[27] J. Haroche,et al. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. , 2015, Hematology. American Society of Hematology. Education Program.
[28] V. Bigley,et al. Cell(s) of Origin of Langerhans Cell Histiocytosis. , 2015, Hematology/oncology clinics of North America.
[29] L. Weiss,et al. BRAF V600E mutation-specific immunohistochemistry is a rare finding in dendritic cell- and histiocyte-derived tumors , 2015, Leukemia & lymphoma.
[30] M. Merad,et al. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? , 2015, British journal of haematology.
[31] M. Hicks,et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. , 2014, The Journal of pediatrics.
[32] K. Hoang-Xuan,et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib , 2014, Neurology.
[33] H. Cualing,et al. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. , 2014, Cancer control : journal of the Moffitt Cancer Center.
[34] A. Tzankov,et al. Unique Composite Hematolymphoid Tumor Consisting of a Pro-T Lymphoblastic Lymphoma and an Indeterminate Dendritic Cell Tumor: Evidence for Divergent Common Progenitor Cell Differentiation , 2014, Pathobiology.
[35] Larissa V Furtado,et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.
[36] H. Cha,et al. Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasms , 2014, Histopathology.
[37] A. Tzankov,et al. Follicular lymphoma transformation into histiocytic sarcoma: indications for a common neoplastic progenitor , 2014, Leukemia.
[38] B. Rollins,et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. , 2014, Blood.
[39] M. Merad,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2014, The Journal of experimental medicine.
[40] J. B. Oliveira. The expanding spectrum of the autoimmune lymphoproliferative syndromes , 2013, Current opinion in pediatrics.
[41] Annette S. Kim,et al. Hemophagocytic Lymphohistiocytosis An Update on Diagnosis and Pathogenesis , 2013 .
[42] Shigeo Nakamura,et al. Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification. , 2013, Journal of clinical and experimental hematopathology : JCEH.
[43] M. Copin,et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. , 2012, Blood.
[44] B. Cheson,et al. Histiocytic sarcoma transdifferentiated from follicular lymphoma presenting as a cutaneous tumor , 2011, Journal of cutaneous pathology.
[45] D. Parham,et al. Langerhans Cell Histiocytosis Preceding the Development of Juvenile Xanthogranuloma: A Case and Review of Recent Developments , 2011, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[46] E. Jaffe,et al. Clonally related Histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: A study of 7 cases , 2011, Modern Pathology.
[47] Dan M. Jones. Histiocytic and Dendritic Cell Neoplasms. , 2010, Surgical pathology clinics.
[48] W. Hahn,et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.
[49] L. Rybak,et al. Primary Rosai-Dorfman Disease of Bone: A Clinicopathologic Study of 15 Cases , 2010, The American journal of surgical pathology.
[50] U. Surti,et al. Clinicopathologic Features of Histiocytic Lesions following ALL, with a Review of the Literature , 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[51] M. Datto,et al. Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a ‘transdifferentiation’ during the clonal evolution , 2010, Leukemia & lymphoma.
[52] R. Warnke,et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. , 2008, Blood.
[53] W. Klapper,et al. Clonality in juvenile xanthogranuloma. , 2007, The American journal of surgical pathology.
[54] K. Chang,et al. Extranodal Rosai-Dorfman Disease Involving the Bone Marrow: A Case Report , 2006, The American journal of surgical pathology.
[55] S. Bray,et al. Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? , 2006, Human pathology.
[56] E. Jaffe,et al. Histologic Features of Sinus Histiocytosis With Massive Lymphadenopathy in Patients With Autoimmune Lymphoproliferative Syndrome , 2005, The American journal of surgical pathology.
[57] A. Attarbaschi,et al. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study , 2005, Leukemia & lymphoma.
[58] R. Egeler,et al. Histiocytic disorders of children and adults , 2005 .
[59] K. Chang,et al. Histiocytic lesions involving the bone marrow. , 2003, Seminars in diagnostic pathology.
[60] B. Beuthien-Baumann,et al. Simultaneous occurrence of Hodgkin's lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. , 2002, Clinical lymphoma.
[61] R. Warnke,et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases , 2002, Histopathology.
[62] S. Fosså,et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. , 2000, Journal of the National Cancer Institute.
[63] S. Dement. Association between mediastinal germ cell tumors and hematologic malignancies: an update. , 1990, Human pathology.